Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis - Takeaways - MDSpire

Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis

  • By

  • Qinyun Chen

  • Jie Zhou

  • Hongli Zhou

  • Hao Wang

  • Jianhua Li

  • May 20, 2026

  • 0 min

Share

  • 1

    Liver-directed therapy combined with immune checkpoint inhibitors (ICIs) showed the best overall survival and progression-free survival in metastatic uveal melanoma.

  • 2

    Tebentafusp demonstrated the second-best overall survival but the worst progression-free survival among the evaluated treatment modalities.

  • 3

    Immune checkpoint inhibitors were less effective than tebentafusp for overall survival but better for progression-free survival in metastatic uveal melanoma.

  • 4

    Targeted therapy and liver-directed therapy provided more favorable outcomes compared to conventional systemic chemotherapy in metastatic uveal melanoma.

  • 5

    Future studies should include emerging therapies for metastatic uveal melanoma, as current options show limited efficacy and poor survival rates.

Original Source(s)

Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis

  • by Qinyun Chen, Jie Zhou, Hongli Zhou, Hao Wang, Jianhua Li

  • May 20, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential